Institutional investors hold a majority ownership of IMGN through the 94.09% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2016, these large investors purchased a net $4.5 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
SIMPLEX TRADING LLC Bought 23.4 Thousand shares of ImmunoGen Inc
CREATIVE PLANNING, INC. Bought 9.1 Thousand shares of ImmunoGen Inc
CUTLER GROUP LP Bought 9.1 Thousand shares of ImmunoGen Inc